Understanding and creating value from open source drug discovery for neglected tropical diseases

Expert Opinion on Drug Discovery

Volumn 7, Issue 8, 2012, Pages 643-657

  Allarakhia, Minna ^a   Ajuwon, Larry ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b Genzyme Europe   (Netherlands)

Author keywords

Human capacity development; Neglected tropical diseases; Open source drug discovery; Value assessment

Indexed keywords

DRUG INDUSTRY; ENDEMIC DISEASE; HEALTH SERVICE; HUMAN; INFORMATION DISSEMINATION; MEDICAL ASSESSMENT; MEDICAL LITERATURE; NEGLECTED DISEASE; NEGLECTED TROPICAL DISEASE; OPEN SOURCE STRATEGY; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PUBLIC-PRIVATE PARTNERSHIP; PUBLICATION; REVIEW; TROPICAL DISEASE;

COOPERATIVE BEHAVIOR; DRUG DISCOVERY; HUMANS; NEGLECTED DISEASES; PROGRAM DEVELOPMENT; TROPICAL MEDICINE;

EID: 84864352043     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2012.690390     Document Type: Review

References (68)

1. Hunter J, Stephens S. Is open innovation the way forward for big pharma? Nat Rev Drug Discov 2010;9:87-8
2. Munos B. Can open-source drug R&D repower pharmaceutical innovation? Clin Pharmacol Ther 2010;87(5):534-6
3. Wagner J. Open-minded to open innovation and precompetitive collaboration. Clin Pharmacol Ther 2010;87(5):511-15
4. Wagner JA, Prince M, Wright EC, et al. The biomarkers consortium: Practice and pitfalls of open-source precompetitive collaboration. Clin Pharmacol Ther 2010;87(5):539-42
5. Weigelt J. The case for open-access chemical biology. EMBO Rep 2009;10(1):941-5
6. Edwards A. Open-source science to enable drug discovery. Drug Discov Today 2008;13(17/18):731-3
7. Hess C, Ostrom E. Understanding knowledge as a commons: From theory to practice. MIT Press; Cambridge: 2006
8. Foray D. The economics of knowledge. MIT Press; Cambridge: 2004
9. Allarakhia M, Kilgour DM, Fuller D. Modeling the incentive to participate in open source biopharmaceutical innovation. R D Manag 2010;40(1):50-66
10. Reichman JH, Dedeurwaerdere T, Uhlir PF. Designing the microbial research commons: Global intellectual property strategies for assessing and using essential knowledge assets. 2010; under review
11. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 2006;5(11):941-55 (Pubitemid 44660607)
12. Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2006;2(12):701-10 (Pubitemid 44764212)
13. Allarakhia M, Strandburg K. A Cultural Commons Study of New Approaches to Drug Development. Case Studies from the Fight Against Malaria, Convening Cultural Commons, Conference of the Engelberg Center on Innovation Law & Policy; 2011
14. Ardal C, Alstadsater A, Røttingen J-A. Common characteristics of open source software development and applicability for drug discovery: A systematic review. Health Res Policy Syst 2011;9:36
15. Chesbrough HW. The era of open innovation. MIT Sloan Manag Rev 2003;44:35-41 (Pubitemid 40830200)
16. Chesbrough HW, Vanhaverbeke W, West J. Open Innovation: Researching a new paradigm. Oxford University Press; Oxford: 2006
17. Masum H, Harris R. Open Source for Neglected Diseases: CHALLENGES and Opportunities. Center for Global Health R&D Policy Assessment; 22 February 2011
18. Chan L, Kirsop B, Arunachalam S. Towards open and equitable access to research and knowledge for development. PLoS Med 2011;8(3):e1001016
19. Madison MJ, Frischmann B, Strandburg K. Constructing commons in the cultural environment. Cornell Law Rev 2010;95:657-710
20. Ostrom E, Gardner R, Walker J. Rules, games and common-pool resources. University of Michigan Press; Ann Arbor: 1994
21. Allarakhia M, Walsh S. Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry. Technovation 2011;31(2-3):105-17
22. Banzi R, Moja L, Pistotti V, et al. Conceptual frameworks and empirical approaches used to assess the impact of health research: An overview of reviews. Health Res Policy Syst 2011;9(1):26
23. Todd MH. Open access and open source in chemistry. Chem Cent J 2007;1:3
24. Aksoy S. Solutions to neglected tropical diseases require vibrant local scientific communities. PLoS Negl Trop Dis 2010;4(3):e662
25. Available from: Www.plosntds.org [Last accessed 15 February 2012]
26. Antelman K. Do open access articles have a greater research impact?, college & research libraries news. American Library Association; US 2004. p. 372-382
27. Weiss D. Measuring success of open source projects using web search engines. The First International Conference on Open Source Systems; 24 October 2005
28. Barnes MR, Harland L, Foord SM, et al. Lowering industry firewalls: Pre-competitive informatics initiatives in drug discovery. Nat Rev Drug Discov 2009;9:701-8
29. Available from: Www.ebi.ac.uk/chemblntd [Last accessed 15 February 2012]
30. Maurer SM, Rai A, Sali A. Finding cures for tropical diseases: Is open source an answer? PLoS Med 2004;1(3):e56
31. Orti L, Carbajo RJ, Pieper U, et al. A kernel for open source drug discovery in tropical diseases. PLoS Negl Trop Dis 2009;3(4):e418
32. Everts S. Online research communities aim to unite scientists worldwide to find cures for neglected disease. Chem Eng News 2006;84(30):34-5
33. Woelfle M, Olliaro P, Todd MH. Open science is a research accelerator. Nat Chem 2011;3:745-8
34. Magarinos MP, Carmona SJ, Crowther GJ, et al. TDR targets: A chemogenomics resource for neglected diseases. Nucleic Acids Res 2012;40(D1):D1118-27
35. Available from: Tdrtargets.org [Last accessed 22 February 2012]
36. Ridley RG, Fletcher ER. Making a difference: 30 years of TDR. Nat Rev Microbiol 2008;6(5):401-7 (Pubitemid 351552661)
37. Crowther GJ, Shanmugam D, Carmona SJ, et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. PLoS Negl Trop Dis 2010;4(8):e804
38. Available from: Www.malariagen.com [Last accessed August 2011]
39. Bhardwaj A, Scaria V, Raghava GP, et al. Open Source Drug Discovery Consortium, Brahmachari SK. Open source drug discovery: A new paradigm of collaborative research in tuberculosis drug development. Tuberculosis 2011;91(5):479-86
40. Available from: Www.osdd.net [Last accessed 15 February 2012]
41. Hurlimann E, Schur N, Boutsika K, et al. Toward an open-access global database for mapping, control, and surveillance of neglected tropical diseases. PLoS Negl Trop Dis 2011;5(12):e1404
42. Available from: Www.gntd.org [Last accessed 22 February 2012]
43. New research identifies promising leads to follow in search for medicines to fight malaria. GSK; 19 May 2010
44. Edlin C. The importance of patent sharing in neglected disease drug discovery. Future Med Chem 2011;3(11):1331-4
45. Rai AK, Reichman JH, Uhlir PF, Crossman CR. Pathways across the valley of death: Novel intellectual property strategies for accelerated drug discovery. Yale J Health Policy Law Ethics 2008;8(1):53-89
46. Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re: SEARCH. WIPO; 26 October 2011
47. WIPO NTD Consortium Access Provisions Set a Bad Precedent by Excluding Countries & Patients. MSF; October 26 2011
48. Drugs for Neglected Diseases Initiative. DNDi Joins WIPO Open Innovation Platform But Calls for More Ambitious Provisions for Innovation and Access. DNDi; 26 October 2011
49. Kapczynski A, Chaifetz S, Benkler Y, Katz Z. Addressing global health inequities: An open licensing approach for University Innovations. Berkeley Technol Law J 2005;20:1031-114
50. Scott WL, O'Donnell MJ. Distributed drug discovery, part 1: Linking academia and combinatorial chemistry to find drug leads for developing world diseases. J Comb Chem 2009;11(1):3-13
51. IUPUI Chemists Develop Distributed Drug Discovery: FINDING Drugs for Neglected Diseases. IUPUI; June 15 2009
52. Correa P. Scientists use global computer network to find leishmaniasis drugs. SciDev.Net, September 302011
53. Scott C, Nunez M. Grid Computing guiding malaria drug discovery. SciDev. Net, May 112009
54. Stevens R, McEntire R, Goble C, et al. Grid and the drug discovery process. Drug Discovery Today 2004;2(4):140-8
55. Chesler EJ, Baker EJ. The importance of open-source integrative genomics to drug discovery. Curr Opin Drug Discov Devel 2010;13(3):310-16
56. Reichman JH, Uhlir PF. A contractually reconstructed research commons for scientific data: International considerations. In: ESSANU JM, Uhlir PF, editors. Open access and the public domain in digital data and information for science: Proceedings of an international symposium. National Academics Press; Washington: 2004. p. 98-102
57. Uhlir PF. Designing the microbial commons: Proceedings of an international workshop. The National Academies Press; Washington DC: 2011
58. Guth RA. Glaxo tries a linux approach. Wall Street J 2010
59. Joint Policy on Data Sharing, Intellectual Property and Publications. MalariaGen; 15 July 2005
60. Von Lakhani KHippel EV. How open source software works: Free user-to-user assistance. Res Policy 2003;32(6):923-43
61. Roy A, McDonald PR, Chaguturu R. Recent trends in collaborative, open source drug discovery. Open Conf Proc J 2011;2:130-136.
62. Hughes B. A Wellcome experiment in seeding drug discovery. Nat Drug Discov 2010;9(3):178-80
63. Butler D. Open-source science takes on neglected disease. Nature February 4, 2010
64. Wilson ME, Ko AI, Reis MG. Collaborative teaching and learning: A model for building capacity and partnerships to address NTDs. PLoS Negl Trop Dis 2011;5(3):e939
65. Available from: Www.ntd-africa.net/en/fellowships.html [Last accessed 22 February 2012]
66. Globalhealthtrials.tghn.org.
67. Lessi M, Asadullah K. Crowd sourcing in drug discovery. Nat Rev Drug Discov 2011;10(4):241-2
68. WHO roadmap inspires unprecedented support to defeat neglected tropical diseases. WHO, Geneva February 03 2012.